Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Dr. Hana Hybasek Dzurikova
3. October 2024

STEMI Mimics: Spot the Subtle Impostors of Myocardial Infarction

STEMI-mimics-cover

In this article, we explore the most common STEMI mimics, their clinical and ECG characteristics, and the role of advanced diagnostic tools, including AI-driven solutions, in aiding accurate and timely diagnosis.

The diagnosis of ST-Elevation Myocardial Infarction (STEMI) is a time-sensitive clinical challenge with critical implications for morbidity and mortality1. However, identifying a true STEMI based solely on ECG changes is not always straightforward, as a number of other conditions, collectively termed STEMI mimics, can produce ST-segment elevations without underlying myocardial infarction2. Misinterpreting these mimics as true STEMI can lead to unnecessary cath lab activations, resulting in invasive procedures that carry inherent risks3.

While the ECG is a crucial rule-in test for STEMI diagnosis, it is not a reliable rule-out test. This means that while significant ST-elevation on an ECG strongly suggests myocardial infarction and warrants urgent action, the absence of these findings does not necessarily exclude acute coronary syndromes (ACS)4. It is critical to correlate ECG findings with the patient’s clinical presentation, symptoms, and additional diagnostic markers, such as troponin levels, to ensure an accurate diagnosis5.

In this article, we explore the most common STEMI mimics, their clinical and ECG characteristics, and the role of advanced diagnostic tools, including AI-driven solutions, in aiding accurate and timely diagnosis.

What Are STEMI Mimics?

STEMI mimics are conditions that cause ST-segment elevation on an ECG but are not due to acute coronary occlusion. These may be cardiac or non-cardiac in origin, and each presents a unique challenge to the clinician2

Unnecessary cath lab activations due to STEMI mimics are relatively common, with studies estimating that approximately 10-36% of patients presenting with ST-segment elevation on ECGs do not have an acute coronary occlusion upon angiography6,7. Misdiagnosing these conditions as STEMI can lead to inappropriate interventions, exposing the patient to potential complications of invasive procedures, such as contrast-induced nephropathy, radiation exposure, bleeding, and others6,7.

The ability to distinguish these mimics is essential for patient safety and resource optimization in busy emergency settings7.

STEMI mimics are conditions that cause ST-segment elevation on an ECG but are not due to acute coronary occlusion. These may be cardiac or non-cardiac in origin, and each presents a unique challenge to the clinician2

Common STEMI Mimics and Their Diagnostic Pitfalls

Some of the most notable conditions mimicking STEMI include subarachnoid hemorrhage, Left Bundle Branch Block (LBBB), pericarditis, spontaneous coronary artery dissection (SCAD), hyperkalemia, ventricular paced rhythm, Brugada syndrome, hypothermia, Prinzmetal’s/Variant angina, pulmonary embolism, Takotsubo cardiomyopathy, ventricular aneurysm, left ventricular hypertrophy, early repolarization, and thoracic aortic dissection. Each of these conditions can present with ECG changes that resemble STEMI, yet they require different treatment approaches, underscoring the importance of careful clinical evaluation8.

Below, we examine several STEMI mimics, focusing on their ECG characteristics, the mechanisms behind their resemblance to STEMI, and some of the key clinical clues that help differentiate them.

STEMI Mimics: Spot the Subtle Impostors of Myocardial Infarction
STEMI Mimics: Spot the Subtle Impostors of Myocardial Infarction

Identify STEMI Mimics with Certified AI

Leverage PMcardio platform to accurately distinguish true myocardial infarctions from STEMI mimics in seconds.

STEMI Mimics: Spot the Subtle Impostors of Myocardial Infarction
STEMI Mimics: Spot the Subtle Impostors of Myocardial Infarction

Pericarditis

Pericarditis, though rarer than myocardial infarction, is an inflammatory condition affecting the pericardium, which can be of infectious (often viral) or non-infectious origin, including autoimmune diseases, cancer, post-cardiac injury syndromes, post-myocardial infarction syndromes, Dressler’s syndrome and others9,11.

ECG Features of Pericarditis

  • Upward concavity of the ST segments, unlike the more horizontal or convex ST elevation often seen in STEMI.
  • Absence of reciprocal changes typically seen in STEMI, except in leads aVR and V1.
  • ST elevation is usually greater in lead II than in lead III, whereas the opposite is a strong indicator of STEMI.
  • Absence of hyperacute T waves – T waves in pericarditis are neither tall nor bulky, with a relatively small area under the curve compared to the QRS complex.
  • PR-segment depression in leads with ST-elevation, particularly in the inferior leads.
  • Absence of reciprocal changes typically seen in STEMI10.
STEMI Mimics ECG Features of Pericarditis
Figure: There is significant ST elevation in multiple leads (V4-6, I, II, III, aVF) with reciprocal ST depression in aVR and V1. Some leads show large T waves, suggestive of hyperacute T waves, while others, such as aVF, display ST elevation without prominent T waves. In distinguishing between conditions like OMI and pericarditis, it’s important to note that occlusion myocardial infarction (OMI) typically shows both large T waves and significant ST elevation, whereas pericarditis often presents with relatively smaller T waves in comparison to the degree of ST elevation. In this case, the patient was ultimately diagnosed with traumatic uncomplicated pericarditis. (Dr. Smith’s ECG Blog, digitized by PMcardio).

Clinical Clues

  • Sharp, pleuritic chest pain that worsens with inspiration or lying down and improves when sitting upright.
  • Pericardial friction rub on auscultation.
  • Absence of elevated troponin levels, or mild elevation if myocarditis is also present10.

How Pericarditis Mimics STEMI

Pericarditis can lead to localized ST elevation, but unlike STEMI, it typically lacks reciprocal ST depression, except in leads aVR and V1. Both conditions can produce concave ST elevation, but only STEMI typically results in convex or horizontal ST elevation. Additionally, if the ST elevation is greater in lead III than in lead II, this is a strong indicator of STEMI. PR-segment depression is mostly associated with viral pericarditis and tends to be a transient, early feature, lasting only a few hours12.

Left Ventricular Hypertrophy (LVH)

LVH results from chronic pressure overload, often due to long-standing hypertension or aortic stenosis. The hypertrophied myocardium alters the electrical conduction patterns, leading to ST-segment abnormalities on the ECG13.

ECG Features of Left Ventricular Hypertrophy:

  • High-voltage QRS complexes, especially in the precordial leads (V1-V6).
  • ST-segment elevation is predominantly observed in the anterior leads (V1-V3), often accompanied by T-wave inversions. This elevation typically occurs in the context of high-voltage S-waves, with the ST/S ratio generally being less than 0.15. An ST/S ratio exceeding 0.15 suggests that the findings are unlikely to be attributable to left ventricular hypertrophy (LVH) (Smith, personal experience).
  • Strain pattern with ST-depression and T-wave inversions in the lateral leads14.
Stemi Mimics ECG Left Ventricular Hypertrophy
Figure: There is deep ST depression and T-wave inversions that are discordant with the large voltage R-waves, which are reflective of profound left ventricular hypertrophy (LVH) as confirmed by the echo. These ST-T changes do not represent ischemia but are secondary to the significant depolarization abnormalities caused by the increased LV mass. However, these changes could potentially mask underlying ischemia. (Dr. Smith’s ECG Blog, digitized by PMcardio).

Clinical Clues

  • History of hypertension or aortic valve disease.
  • Echocardiographic evidence of hypertrophy.

How LVH Mimics STEMI

The elevated voltage in the anterior leads and associated strain pattern can mimic an anteroseptal infarction. LVH-induced repolarization abnormalities can lead to confusion, especially in the absence of a clear clinical picture of ACS15 and is frequently identified as a cause of ‘false-positive’ emergent angiography34.

Early Repolarization

Early repolarization is a benign ECG variant most commonly seen in young, healthy individuals, particularly athletes. It represents a variation in the electrical activity of the heart’s repolarization phase16.

ECG Features of Early Repolarization

  • ST-segment elevation, typically concave, in the precordial and inferior leads.
  • Notching or slurring of the J-point, especially in the lateral leads.
  • No reciprocal ST-segment depression or evolving ECG changes17.
STEMI Mimics Early Repolarization
Figure:New diffuse ST elevation with a QTc of 384 and a formula of 19.1. The ST axis is approximately 30 degrees, with ST elevation in leads I, aVL, II, and aVF but not III, and no reciprocal ST depression except in aVR. This pattern is characteristic of pericarditis or diffuse early repolarization. Given the high T-wave voltage and elevated T/ST ratio, early repolarization is more likely. Well-formed J-waves are also present, further supporting early repolarization. Note the asymmetry of the T-waves, characterized by a slow upstroke and rapid downstroke. In contrast, hyperacute T-waves are not necessarily taller than those seen in early repolarization but are typically bulkier, with a larger area under the curve, more symmetric morphology, reduced upward concavity, and a higher T-wave to R-wave amplitude ratio. This distinction arises because the QRS complex is generally smaller in MI compared to early repolarization. (Dr. Smith’s ECG Blog, digitized by PMcardio)35.

Clinical Clues

  • Asymptomatic or discovered incidentally.
  • No associated chest pain or cardiac risk factors16,18.

How Early Repolarization Mimics STEMI

Early repolarization can closely mimic the ST-elevations seen in anterior or inferior STEMI, especially when J-point notching or slurring is present. Differentiation relies on the absence of clinical symptoms, reciprocal changes, and the stability of the ECG over time16.

Left Ventricular Aneurysm

Left ventricular aneurysm (LVA) is a condition that typically develops as a late complication following a myocardial infarction (MI). It results from scar tissue formation in the left ventricular wall, leading to a localized area that bulges outward during systole. Unlike acute coronary syndromes like STEMI, LVA is a chronic state rather than an acute event, yet its ECG findings can closely resemble those of a myocardial infarction, making differentiation essential to avoid misdiagnosis37.

ECG Features of Left Ventricular Aneurysm

  • Persistent ST Elevation: ST elevation in LVA is usually chronic, persisting weeks to months after an MI. It is often localized to the leads corresponding to the area of the scarred myocardium, most commonly the anterior leads (V1-V6). This elevation is typically concave and less pronounced compared to the acute elevation seen in STEMI37.
  • Absence of Reciprocal Changes: Unlike STEMI, which often presents with reciprocal ST depression in opposing leads, LVA usually lacks these changes37.
  • T-Wave Characteristics: In LVA, T waves are not hyperacute but rather diminished and flattened compared to the QRS complex. A key differentiator is the ratio of T-wave to QRS amplitude. According to Smith, a T/QRS ratio greater than 0.36 is suggestive of acute MI rather than LVA36 .
  • Q Waves: Deep, persistent Q waves are often seen in the same leads as the ST elevation. These Q waves indicate myocardial necrosis rather than active ischemia37.
STEMI Mimics: Spot the Subtle Impostors of Myocardial Infarction
Figure: The ECG shows significant ST elevation across the precordial leads, with the highest elevation in V2 and V3. These leads display minimal R-wave presence, effectively creating “QS” waves – deep Q-waves without any preceding R-wave – alongside markedly deep S-waves.  Dramatically biphasic T-waves show steep descents, resembling Wellen’s pattern, but poor R-wave progression rules out true Wellen’s syndrome, which requires R-wave preservation. Additionally, this patient reported no recent ischemic symptoms typical of Wellen’s. The deep S waves and ST elevation may suggest left ventricular hypertrophy, but the absence of high-voltage R-waves in V4-V6 excludes this. The findings are consistent with “persistent STE after prior MI,” also referred to as “left ventricular aneurysm morphology”. (Dr. Smith’s ECG Blog, digitized by PMcardio)

Clinical Clues

  • History of Prior MI: A history of MI weeks to months earlier is a critical clinical clue when interpreting persistent ST elevation.
  • Absence of Acute Symptoms: Patients with LVA often lack the acute chest pain typical of STEMI. Symptoms, if present, may relate to heart failure or arrhythmias rather than acute ischemia.
  • Troponin Levels: Troponin levels in LVA are typically not elevated, or they may be mildly elevated if there is concurrent myocardial stress or small areas of ongoing ischemia37.

How LVA Mimics STEMI

LVA can cause persistent ST elevation in anterior leads that closely resembles the pattern seen in an anterior STEMI. However, the chronicity and lack of reciprocal changes differentiate it from an acute MI. Additionally, while STEMI often results in convex or horizontal ST elevation, LVA usually maintains a concave ST pattern. Notably, the presence of deep Q waves in the affected leads and a diminished T/QRS amplitude ratio are further distinguishing factors36,37.

Previously Diagnosed Left Bundle Branch Block (LBBB)

LBBB is a conduction abnormality that affects the left ventricle, causing delayed depolarization and abnormal repolarization patterns. While an old, previously diagnosed LBBB often reflects underlying structural heart disease or chronic conditions, distinguishing whether it is new or old may not significantly impact the incidence of an acute myocardial infarction.

The most critical aspect in assessing ischemia in the context of LBBB is the application of the Smith Modified Sgarbossa Criteria, which is currently the most sensitive set of criteria available for identifying OMI in LBBB cases.

However, it is important to note that, despite being more sensitive than traditional STEMI criteria used in patients with normal conduction, the Smith Modified Sgarbossa Criteria may still miss a substantial portion of cases. This makes the interpretation of the ECG in the context of LBBB particularly challenging, especially when other clinical signs of ischemia are present20.

ECG Features of Previously Diagnosed LBBB

  • Wide QRS complexes (>120ms).
  • Discordant ST-segments (ST-segment elevation in leads with a predominantly negative QRS and depression in leads with positive QRS complexes).
  • Absence of normal septal Q-waves in leads I, aVL, V5, and V621.
STEMI Mimics ECG Features of Previously Diagnosed LBBB ECG
Figure: Sinus rhythm with LBBB and appropriate discordant ST changes: no concordant ST elevation, no concordant ST depression in V1-V3, and no evidence of excessive discordance.  (Dr. Smith’s ECG Blog, digitized by PMcardio Digitize).

Clinical Clues

  • Often seen in patients with underlying cardiomyopathy or ischemic heart disease.
  • Symptomatology may range from asymptomatic to severe heart failure19.

Why LBBB Mimics STEMI

LBBB creates significant abnormalities in both the depolarization and repolarization of the ventricles, making it difficult to interpret ST-segments. This necessitates the use of additional diagnostic tools, such as coronary angiography, or more sophisticated ECG interpretation models, like PMcardio, which can accurately interpret complex conduction abnormalities in LBBB and paced rhythms22.

STEMI Mimics: Spot the Subtle Impostors of Myocardial Infarction
STEMI Mimics: Spot the Subtle Impostors of Myocardial Infarction

Identify STEMI Mimics with Certified AI

Leverage PMcardio platform to accurately distinguish true myocardial infarctions from STEMI mimics in seconds.

STEMI Mimics: Spot the Subtle Impostors of Myocardial Infarction
STEMI Mimics: Spot the Subtle Impostors of Myocardial Infarction

Ventricular Paced Rhythm

Ventricular paced rhythm (VPR) is characterized by an artificial pacing stimulus from a pacemaker that creates a wide QRS complex resembling a LBBB. This makes the ECG interpretation of MI challenging, as the usual ST-segment changes seen in ACS may be masked or altered in the presence of pacing. However, the Modified Sgarbossa Criteria have been validated as effective in diagnosing acute coronary occlusion in VPR, aiding clinicians in identifying MI when standard criteria might fail38.

ECG Features of Ventricular Paced Rhythm

  • Discordant ST Elevation: The Modified Sgarbossa Criteria use the degree of discordance between the ST-segment and the QRS complex. An ST-segment elevation greater than 25% of the preceding S-wave amplitude in any lead indicates MI38.
  • Concordant ST Elevation or Depression: Concordant ST elevation (ST elevation in the same direction as the QRS complex) of ≥1 mm in any lead also supports the diagnosis of acute MI in VPR. Concordant ST depression in leads V1-V3 is another key indicator36.
  • Absence of Hyperacute T Waves: In contrast to typical ST-elevation myocardial infarction (STEMI), hyperacute T waves may not be present in VPR. T waves in VPR are often discordant, making it difficult to distinguish them from baseline abnormalities caused by the pacing.

Clinical Clues

  • Patient History and Symptoms: Symptoms of chest pain and history of coronary artery disease are critical in suspecting an MI in the context of VPR.
  • Troponin Elevation: Elevated troponin levels alongside the ECG criteria mentioned can confirm the diagnosis.
  • Advanced Imaging: Given the diagnostic difficulties, further imaging modalities like echocardiography may be necessary to support the findings36.

How Ventricular Paced Rhythm Mimics STEMI 

VPR can obscure classic STEMI findings due to the wide QRS and altered ST-segments caused by pacing. This overlap necessitates the use of modified criteria to accurately diagnose acute MI, as standard STEMI criteria are often not applicable. Proper application of the Modified Sgarbossa Criteria helps in distinguishing true occlusive MI from baseline ECG abnormalities related to pacing38.

Brugada Syndrome

Brugada syndrome is a genetic condition affecting the sodium channels of the cardiomyocytes, specifically through mutations in the SCN5A gene, predisposing individuals to ventricular arrhythmias and sudden cardiac death23,24.

ECG Features of Brugada Syndrome

  • ST-segment elevation in the right precordial leads (V1-V3) with a coved or saddleback pattern25.
  • T-wave inversion in the right precordial leads.
  • Right bundle branch block (RBBB) pattern may also be present26.
STEMI Mimics Brugada Syndrome ECG Features
Figure: Sinus rhythm with a mostly normal QRS. Abnormal ST elevation in V1-V3 and possible ST depression in V5-6 could suggest anterior/septal/RV OMI, but V2 morphology may also indicate a Brugada pattern or phenocopy. Given this patient’s symptoms of weakness and fever, without chest pain or dyspnea, Brugada pattern is much more likely. (Dr. Smith’s ECG Blog, digitized by PMcardio)

Clinical Clues

  • Typically presents in young men with a history of syncope, palpitations, or sudden cardiac arrest23.
  • Family history of sudden cardiac death or arrhythmias24.
  • Typically presents without chest pain and can be exacerbated by fever, which increases the risk of arrhythmias due to the temperature sensitivity of sodium channels27.

How Brugada Syndrome Mimics STEMI

Brugada syndrome can present with ST-segment elevation in the anterior leads, mimicking a STEMI involving the LAD territory. The absence of reciprocal changes and the coved morphology of the ST-elevation are key distinguishing features25.

Hyperkalemia

Hyperkalemia alters cardiac depolarization and repolarization due to elevated extracellular potassium levels, affecting the resting membrane potential of cardiac myocytes28.

ECG Features of Hyperkalemia

  • Peaked T-waves, particularly in the precordial leads.
  • Flattening or absence of P-waves.
  • Wide QRS complexes that can merge with ST-segments, creating a sine-wave appearance in severe cases29.
STEMI Mimics: Spot the Subtle Impostors of Myocardial Infarction
Figure: The ECG shows a probable junctional rhythm with a wide QRS duration of 162 ms and peaked T-waves. Additionally, there is ST elevation in leads III and aVF, with reciprocal ST depression observed in leads I and aVL. There is also ST depression present in leads V2 and V3, further suggesting an ischemic pattern. These findings are in line with hyperkalemia. (Dr. Smith’s ECG Blog, digitized by PMcardio)

Clinical Clues

  • History of renal failure, potassium-sparing diuretic use, or other causes of hyperkalemia.
  • Symptoms of muscle weakness, fatigue, or arrhythmias28,30.

How Hyperkalemia Mimics STEMI

Severe hyperkalemia can cause broad ST-elevation and wide QRS complexes that may resemble ischemic changes on the ECG. The absence of reciprocal changes, the clinical context, and rapid normalization of the ECG after correcting potassium levels are important clues31.

Pulmonary Embolism 

Pulmonary embolism (PE) is a potentially life-threatening condition characterized by a blood clot obstructing a pulmonary artery. While PE primarily causes respiratory symptoms, it can sometimes mimic STEMI on an ECG, complicating diagnosis and treatment.

ECG Features of Pulmonary Embolism 

  • S1Q3T3 Pattern: The classic ECG finding in PE is an S wave in lead I, a Q wave, and an inverted T wave in lead III (S1Q3T3). However, this pattern is neither sensitive nor specific for PE39.
  • Tachycardia: Sinus tachycardia is the most common ECG finding, although it is nonspecific and can be seen in various conditions39.
  • ST Elevation Mimicry: PE can occasionally produce ST elevation in the inferior and anterior leads, resembling a myocardial infarction. Differentiating these conditions requires clinical correlation and imaging to confirm PE39.

Clinical Clues

  • Dyspnea and Pleuritic Chest Pain: Unlike STEMI, PE is often associated with respiratory symptoms such as sudden dyspnea and pleuritic chest pain.
  • Hypoxia: Hypoxia and elevated D-dimer levels may support the diagnosis of PE.
  • Troponin Elevation: Mild troponin elevation may be seen in PE, but it is usually not as pronounced as in an acute MI.

How It Mimics STEMI

PE can lead to right heart strain, causing ST elevation and T wave inversions that mimic STEMI. However, unlike STEMI, the ST changes in PE often appear in atypical distributions and lack the reciprocal changes typical of myocardial infarction. A high clinical suspicion and the use of imaging studies such as CT pulmonary angiography are crucial for correct diagnosis39.

The Role of Advanced Diagnostics in Identifying STEMI Mimics

In the high-pressure environment of emergency care, where minutes matter, distinguishing between true STEMI and STEMI mimics can be a daunting task. While clinical context, patient history, and laboratory findings (such as troponin levels) are essential, the ECG remains the cornerstone of diagnosis. However, traditional ECG interpretation can be challenging in the presence of conduction abnormalities, hypertrophic changes, or benign variants.

This is where PMcardio offers a distinct advantage. By utilizing advanced deep learning algorithms trained on extensive datasets of ECGs, our AI is capable of distinguishing true myocardial infarction from common STEMI mimics with high precision22. The tool analyzes patterns that may be difficult to detect with the naked eye, reducing unnecessary cath lab activations and invasive procedures.

Dr. Robert Herman, CMO of Powerful Medical, shares insights at ESC Congress 2024 from an international validation study on the PMcardio AI ECG model for detecting acute coronary occlusion, regardless of ST-elevation, enabling clinicians accurately distinguish true myocardial infarctions from STEMI mimics in seconds.

Conclusion

STEMI mimics pose a significant challenge to emergency care providers, with the potential for both over- and under-treatment of patients presenting with chest pain and ST-segment elevation. Careful ECG interpretation, clinical context, and advanced diagnostic tools are essential in differentiating these conditions from true STEMI. PMcardio, the AI-powered ECG platform offers clinicians an invaluable tool in making these critical decisions, ensuring that patients receive the right diagnosis and treatment32,33.

References

  1. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119-177.
  2. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. Circulation. 2013;127(4).
  3. Naidu SS, Abbott JD, Bagai J, Blankenship J, Garcia S, Iqbal SN, et al. SCAI expert consensus update on best practices in the cardiac catheterization laboratory: endorsed by the American College of Cardiology, the American Heart Association, and the Heart Rhythm Society. Catheter Cardiovasc Interv. 2021;98(2):255-276. doi:10.1002/ccd.29744.
  4. Moak JH, Muck AE, Brady WJ. ST-segment elevation myocardial infarction mimics: The differential diagnosis of nonacute coronary syndrome causes of ST-segment/T-wave abnormalities in the chest pain patient. Turk J Emerg Med. 2024;24(4):206-217.
  5. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Circulation. 2018;138(20).
  6. Larson DM, Menssen KM, Sharkey SW, et al. “False-positive” cardiac catheterization laboratory activation among patients with suspected ST-segment elevation myocardial infarction. JAMA. 2007;298(23):2754-2760. doi:10.1001/jama.298.23.2754.
  7. McCabe JM, Armstrong EJ, Kulkarni A, et al. Prevalence and factors associated with false-positive ST-segment elevation myocardial infarction diagnoses at primary percutaneous coronary intervention-capable centers: A report from the Activate-SF registry. Arch Intern Med. 2012;172(11):864-871. doi:10.1001/archinternmed.2012.157.
  8. Daley SM. STEMI mimics: A mnemonic. Available from: https://litfl.com/stemi-mimics-a-mnemonic [Accessed September 2024]
  9. Imazio M, Gaita F, LeWinter M. Evaluation and Treatment of Pericarditis: A Systematic Review. JAMA. 2015;314(14):1498-1506. doi:10.1001/jama.2015.12763.
  10. Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the Diagnosis and Management of Pericardial Diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2015;36(42):2921-2964. doi:10.1093/eurheartj/ehv318.
  11. Spodick DH. Acute Pericarditis: Current Concepts and Practice. JAMA. 2003;289(9):1150-1153. doi:10.1001/jama.289.9.1150.
  12. Pericarditis ECG Library. Life in the Fast Lane. Available from: https://litfl.com/pericarditis-ecg-library/. [Accessed 24 September 2024].
  13. Hancock EW, Deal BJ, Mirvis DM, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part V: electrocardiogram changes associated with cardiac chamber hypertrophy: a scientific statement from the American Heart Association. Circulation. 2009;119(10). doi:10.1161/CIRCULATIONAHA.108.191097.
  14. Goldberger AL. Clinical Electrocardiography: A Simplified Approach. 8th ed. Philadelphia: Elsevier; 2012.
  15. Okin PM, Devereux RB, Nieminen MS, et al. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the LIFE Study. Eur Heart J. 2009;30(6):714-721. doi:10.1093/eurheartj/ehp008.
  16. Macfarlane PW, Antzelevitch C, Haissaguerre M, Huikuri HV, Potse M, Rosso R, et al. The Early Repolarization Pattern: A Consensus Paper. J Am Coll Cardiol. 2015;66(4):470–7.
  17. Rezus C, Floria M, Moga VD, Sirbu O, Dima N, Ionescu SD, Ambarus V. Early repolarization syndrome: electrocardiographic signs and clinical implications. Ann Noninvasive Electrocardiol. 2014 Jan;19(1):15-22. doi: 10.1111/anec.12113. Epub 2013 Sep 30. PMID: 24118137; PMCID: PMC6932182.
  18. Klatsky AL, Oehm R, Cooper RA, Udaltsova N, Armstrong MA. The early repolarization normal variant electrocardiogram: correlates and consequences. Am J Med. 2003;115(3):171–7.
  19. Birnbaum Y, Wilson JM, Fiol M, de Luna AB, Eskola M, Nikus K. ECG diagnosis and classification of acute coronary syndromes. Ann Noninvasive Electrocardiol. 2014;19(1):4-14.
  20. Sgarbossa EB, Pinski SL, Barbagelata A, Underwood DA, Gates KB, Topol EJ, et al. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. N Engl J Med. 1996;334(8):481-7.
  21. Surawicz B, Childers R, Deal BJ, Gettes LS, Bailey JJ, Gorgels A, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Circulation. 2009;119(10)
  22. Herman R, Meyers HP, Smith SW, Bertolone DT, Leone A, Bermpeis K, et al. International evaluation of an artificial intelligence-powered electrocardiogram model detecting acute coronary occlusion myocardial infarction. Eur Heart J Digit Health. 2023;5(2):123-33. doi:10.1093/ehjdh/ztad074.
  23. Antzelevitch C, Brugada P, Brugada J, Brugada R. Brugada syndrome: From cell to bedside. Heart Rhythm. 2005;2(4):356-60.
  24. Campuzano O, Sarquella-Brugada G, Cesar S, Arbelo E, Brugada J, Brugada R. Update on genetic basis of Brugada syndrome: Monogenic, polygenic or oligogenic? Int J Mol Sci. 2020 Sep 28;21(19):7155. doi: 10.3390/ijms21197155. PMID: 32998306; PMCID: PMC7582739.
  25. Brugada J, Brugada R, Antzelevitch C, Towbin JA, Brugada P. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation. 2002;105(1):73-8.
  26. Mizusawa Y, Wilde AA. Brugada syndrome. Circ Arrhythm Electrophysiol. 2012;5(3):606-16.
  27. Keller DI, Rougier JS, Kucera JP, Benammar N, Fressart V, Guicheney P, et al. Brugada syndrome and fever: genetic and molecular characterization of patients carrying SCN5A mutations. Cardiovasc Res. 2005;67(3):510-9.
  28. Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med. 2000;18(6):721-9.
  29. Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med. 2000 Nov;18(6):721-9. doi: 10.1053/ajem.2000.7344.
  30. Pfortmüller CA, Leichtle AB, Fiedler GM, Exadaktylos AK, Lindner G. Hyperkalemia in the emergency department: etiology, symptoms and outcome of a life-threatening electrolyte disorder. Eur J Intern Med. 2013;24(5) doi: 10.1016/j.ejim.2013.02.010.
  31. Littmann L, Gibbs MA. Electrocardiographic manifestations of severe hyperkalemia. J Electrocardiol. 2018;51(5):814-7. doi: 10.1016/j.jelectrocard.2018.06.018.
  32. Powerful Medical. Clinical validations: PMcardio AI-powered ECG interpretation. Powerful Medical [Internet]. 2023 [cited 2024 Sep 24]. Available from: https://www.powerfulmedical.com/blog/clinical-validations/
  33. Powerful Medical. PMcardio for organizations: AI-powered ECG interpretation. Powerful Medical [Internet]. 2023 [cited 2024 Sep 24]. Available from: https://www.powerfulmedical.com/pmcardio-organizations/
  34. Shamim S, McCrary J, Wayne L, Gratton M, Bogart DB. Electrocardiographic findings resulting in inappropriate cardiac catheterization laboratory activation for ST-segment elevation myocardial infarction. Cardiovasc Diagn Ther. 2014;4(3):215-223. doi:10.3978/j.issn.2223-3652.2014.05.01.
  35. Smith SW, Khalil A, Henry TD, Rosas M, Chang RJ, Heller K, Scharrer E, Ghorashi M, Pearce LA. Electrocardiographic differentiation of early repolarization from subtle anterior ST-segment elevation myocardial infarction. Ann Emerg Med. 2012;60(1):45-56. doi:10.1016/j.annemergmed.2012.02.015.
  36. Smith SW. T-wave amplitude to QRS amplitude ratio best distinguishes the ST elevation of anterior left ventricular aneurysm from anterior acute myocardial infarction. Acad Emerg Med. 2003;10:516–517.
  37. Klein LR, Shroff G, Beeman W, Smith SW. Electrocardiographic Criteria to Differentiate Acute Anterior ST Elevation Myocardial Infarction from Left Ventricular Aneurysm. Am J Emerg Med. 2015;33:786–790.
  38. Dodd KW, Zvosec DL, Hart MA, et al. Electrocardiographic Diagnosis of Acute Coronary Occlusion Myocardial Infarction in Ventricular Paced Rhythm Using the Modified Sgarbossa Criteria. Ann Emerg Med [Internet]. 2021. Available from: http://dx.doi.org/10.1016/j.annemergmed.2021.03.036
  39. Villablanca PA, Vlismas PP, Wiley J, et al. Case report and systematic review of pulmonary embolism mimicking ST-elevation myocardial infarction. Vascular. 2019;27(1):61-68. doi:10.1177/1708538118791917.

Dr. Hana Hybasek Dzurikova

Dr. Hana Hybasek Dzurikova is a medical educator driving innovation and change in health professions education through technology-enhanced learning.
Dr. Hana Hybasek Dzurikova is a medical educator driving innovation and change in health professions education through technology-enhanced learning.
About PMcardio:

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

About Powerful Medical:

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Don't miss these

Powerful Medical team receiving the MedTech Innovator 2025 Mid-Stage Grand Prize award on stage, holding a large winner’s check.

Powerful Medical Wins MedTech Innovator 2025

Powerful Medical has been named MedTech Innovator 2025, winning MTI’s Mid-Stage Grand Finals—top honor from the world’s largest medtech accelerator. The award recognizes PMcardio and its FDA Breakthrough-designated Queen of Hearts™ AI ECG technology, which doubles sensitivity for detecting severe heart attacks and significantly cuts ECG-to-balloon time in large clinical trials.

PMcardio Reports Positive RCT Results and Late-Breaking Clinical Science for STEMI Detection

PMcardio’s AI-powered ECG technology delivers breakthrough results at TCT 2025—improving heart attack detection, reducing false activations, and enabling faster treatment across major clinical trials, including the landmark DIFOCCULT-3 RCT.

Join over 100,000 healthcare professionals who are already taking advantage of AI

Suites

Five suites.
One platform.
The full cardiac care journey.

PMcardio’s clinical suites cover the full spectrum of cardiac care — from acute emergency detection to longitudinal monitoring. Deploy the suites that match your priorities today, expand as your needs grow.

Minutes matter

Acute Care Suite

AI-powered detection and pathway coordination for time-critical cardiac events — including STEMI and OMI, pulmonary embolism / RV strain, and hyperkalemia.

  • stemi/OMI
  • pe/RV strain
  • hyperK

Find what ECGs Hide

Echo Screening Suite

AI-powered screening for structural heart disease directly from a 12-lead ECG — detecting reduced LVEF, aortic stenosis, HCM, and other SHD conditions that traditional ECG interpretation misses.

  • lvef
  • aortic stenosis
  • hcm

Ambulatory, automated

Remote Monitoring Suite

AI-powered analysis of ambulatory ECG recordings — Holter monitors, cardiac patches, and other continuous monitoring devices — with automated findings and longitudinal tracking.

  • holter
  • cardiac patches
  • arrhythmia burden

Beyond the clinic

Patient Suite

AI-powered ECG interpretation for consumer wearables and patient-facing devices — extending cardiac care beyond the clinic into everyday life.

  • wearable ECG Analysis
  • PPG Analysis

On-table intelligence

Angio Suite

AI-powered analysis of coronary angiography — automated stenosis quantification, TIMI frame count, guide wire detection, and myocardial blush grading in near real-time.

  • vessel segmentation
  • stenosis quant.
  • timi frames
  • blush grading

Governance, customization & configuration

Align the platform to your protocols — without a custom software project.

Configure escalation thresholds, roles, and reporting to match local pathway rules — while maintaining system-wide governance and consistency.

  • Configurable triggers, roles, and escalation workflows
  • Custom dashboards and views aligned to leadership needs
  • Controlled expansion to additional pathways over time

Outcomes, QA & performance intelligence​

Measure what matters — across every pathway, every site.

Turn pathway execution into dashboards and reporting that help leadership reduce variation, optimize time-to-treatment, and demonstrate value across every deployed suite.

  • Cross-site, cross-pathway, and team-level benchmarking
  • Time-to-treatment and pathway quality tracking
  • QA workflows, audit trails, and leadership reporting
  • Registry-aligned reporting support (NCDR Chest Pain-MI, AHA GWTG, and more)

Escalation & care coordination

Real-time routing that matches how your system actually runs.

Route critical cases to the right team with role-based notifications, escalation logic, and shared case context — across EMS, ED, cardiology, cath lab, and inpatient care.

  • Role-based alerting and escalation across departments and sites
  • Shared case context so receiving teams have what they need before the patient arrives
  • Integration with existing communication and alerting tools

AI-powered decision support

Clinically validated AI that spans the cardiac care journey.

Run multiple AI models on every recording — acute detection, screening, procedural quantification — with interpretable outputs and case-level explainability.

  • Queen of Hearts™ for STEMI/OMI detection
  • LVsense™ for reduced ejection fraction
  • Culprit Artery Prediction for pre-cath planning
  • Core AI for comprehensive rhythm and conduction analysis
  • Expanding model portfolio across Echo Screening, Remote Monitoring, and Angio Suites

Interoperability & deployment

Connect across your existing systems — without replacing them.

Ingest pathway-critical inputs from across your network and IT landscape, and deliver results where teams already work. Built for system-wide rollout with enterprise deployment patterns.

  • Connect to ECG devices, angiographic systems, and ambulatory monitors across sites
  • Launch PMcardio from the EHR / CVIS with secure links and SSO
  • Send results back to clinical systems where care is documented

All Supported ECG Findings

Rhythms
Sinus bradycardia • Sinus rhythm • Sinus tachycardia • Paced rhythm • Atrial fibrillation
Atrial fibrillation with rapid ventricular response • Atrial fibrillation with slow ventricular response • Atrial flutter • Atrial flutter with rapid ventricular response • Atrial flutter with slow ventricular response • Supraventricular tachycardia • Suspected junctional rhythm • Suspected junctional bradycardia • Suspected accelerated junctional rhythm • Wide QRS rhythm • Idioventricular rhythm • Wide QRS tachycardia

Myocardial Infarctions
  • STEMI
  • STEMI
    Equivalent
Detects occlusive myocardial infarctions (OMIs) even without ST elevation (i.e. posterior STEMI, hyperacute T-waves, etc.). Negative for STEMI mimics (i.e. early repolarization, LVH, etc.)
  • High-Risk NSTEMI
    Represents a type 1 myocardial infarction caused by a transiently recanalized coronary occlusion—classically seen in patterns such as Wellens type A or B due to subtotal LAD obstruction, but possible in any infarct-related territory.
  • Culprit Detection
    AI-predicted likelihood scores for LAD, LCx, and RCA with 3D heart visualization highlighting the predicted culprit artery.

Conduction Abnormalities (Heart Blocks
1st degree AV block • 2nd degree AV block, type Wenckebach • Higher degree AV block • Complete right bundle branch block • Incomplete right bundle branch block • Complete left bundle branch block • Incomplete left bundle branch block • Nonspecific intraventricular conduction delay • Left anterior fascicular block • Left posterior fascicular block • Bifascicular block (RBBB + LAFB) • Bifascicular block (RBBB + LPFB) • Trifascicular block (RBBB + LAFB + AVBLOCK1) • Trifascicular block (RBBB + LPFB + AVBLOCK1)

LVEF
Reduced LVEF (≤40%) • Mildly reduced LVEF (41 – 49%) • No signs of reduced LVEF (≥50%)

Axis
Left cardiac axis deviation • Right cardiac axis deviation • Extreme cardiac axis deviation • Normal axis

Measurements
Heart rate • P wave • PR interval • QRS duration • QT interval • Corrected QT interval (Framingham formula) • RR interval • PP interval • ST elevations

Other Supported Diagnoses
Suspected long QT syndrome • Suspected short QT syndrome • Suspected atrial enlargement • Suspected ventricular hypertrophy • Premature complexes

Dr. Tom De Potter, MD

Cardiologist at the Cardiac Center Aalst

Cardiologist specializing in Pacemaker Device Therapy and Electrophysiology. Leads the electrophysiology unit at the Heart Center in Aalst, holds an executive board position at the European Heart Academy, and serves as EHRA scientific program committee co-chair.

Dr. Martin Penicka, MD, PhD

Cardiologist at the Cardiac Center Aalst

Cardiologist at the Cardiac Center Aalst since 2009, specializing in non-invasive imaging and valvular disease. Fellow of the European Society of Cardiology (FESC) and the European Association of Cardiovascular Imaging (FEACVI).

Dr. Ward Heggermont, MD, PhD

Co-director at the Cardiovascular Center

Co-director at the Cardiovascular Center of Aalst Hospital, specializing in heart failure. Research focus at the intersection of cardiology, virology, and metabolism.

Prof. Dr. Robert Hatala, PhD

Co-founder and Chief Scientist

Head of the Arrhythmia and Pacing department at the National Institute of Cardiovascular Diseases in Slovakia. More than 150 publications and 10,000 citations. Contributor to ESC clinical practice guidelines and executive editor of the European Heart Journal since 2020.

Arieh Levy

Head of PMcardio for Individuals

Arieh leads the PMcardio for Individuals product at Powerful Medical, guiding its development as a clinical tool for emergency physicians, cardiologists, and primary care physicians. He holds a First Class MEng in Biomedical Engineering from Imperial College London, where he specialised in AI for cardiology, building physics-informed neural networks to model atrial electrical properties, giving him a background that bridges the clinical and technical demands of building a certified AI medical device used at the bedside every day.

Dr. Dave Pearson, MD​

Business Advisor

Academic emergency medicine physician, entrepreneur, investor, and researcher with nearly two decades at Atrium Health, one of US largest health systems. Brings expertise at the intersection of clinical care, healthcare innovation, and strategic leadership.

Prof. Stephen W. Smith, MD

Professor of Emergency Medicine

Faculty physician in Emergency Medicine at Hennepin County Medical Center and Professor of Emergency Medicine at the University of Minnesota. Co-inventor of the OMI paradigm and editor of Dr. Smith’s ECG Blog, the most-visited US-based ECG interpretation blog.

Prof. Emanuele Barbato, MD, PhD

President of EAPCI

Interventional cardiologist specializing in coronary artery disease and coronary physiology. Acting president of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and contributor to the clinical practice guidelines for STEMI care.

Scott Sharkey, MD

Chief Medical Officer

Chief Medical Officer of the Minneapolis Heart Institute Foundation and practicing cardiologist at Allina Health Minneapolis Heart Institute. Co-founder of the STEMI Midwest consortium and Takotsubo cardiomyopathy research program and a widely published clinical investigator in STEMI care.

Prof. Dr. Leor Perl, MD

Director of Cardiac Catheterization Institute

Director of Complex Cardiac Interventions and Chief Innovation Officer at Rabin Medical Center. Graduate of the Stanford Biodesign Program.

Suzanne J. Baron, MD, MSc

Director of Interventional Cardiology Research

Director of Interventional Cardiology Research at Massachusetts General Hospital. Holds a Master’s degree in health economics from Harvard School of Public Health. Expert in cardiovascular device impact on healthcare costs and patient-reported outcomes.

Prof. Marco Valgimigli, MD

Deputy Chief Cardiocentro Ticino Institute

Head of Cardiology at Cardiocentro Ticino and Principal Investigator of the TITAN-OMI randomized controlled trial. His research has shaped both European and US clinical practice guidelines on coronary stents, antithrombotic therapy, and vascular access.

Timothy D. Henry, MD

Medical Director of The Carl and Edyth Lindner Center

Leading expert in interventional cardiology and STEMI treatment. Co-founder and principal investigator of the Midwest STEMI Consortium, a registry of more than 20,000 consecutive STEMI activations. Presenting author for the TCT 2025 Late-Breaking Clinical Science on Queen of Hearts.

Matus Horvath

Head of People

Matus leads hiring strategy and culture at Powerful Medical. He previously ran the People Team at Slido, the Slovak SaaS startup later acquired by Cisco — an experience that informs how he builds a high-performing, values-driven team through rapid scaling.

Dr. Timea Kisova, MD

Clinical Research Lead

Timea leads Powerful Medical’s global external validation studies, including the multi-country AI ECG TIMI Study. With a background in biomedical sciences and a medical degree from Barts and The London School of Medicine and Dentistry, she brings the clinical discipline required to generate the prospective, real-world evidence behind every PMcardio module.

Dr. Anthony Demolder, MD, PhD

HF Pathway Lead

Research physician with a PhD on arrhythmias in heritable thoracic aortic disease. He has led international studies at the intersection of cardiology and AI — including earlier work on atrial fibrillation at AZ Sint-Jan Brugge — and now drives Powerful Medical’s heart failure pathway and LVsense™ AI model development.

Dr. Pendell Meyers, MD

ACS Pathway Lead

Emergency medicine physician, prolific educator, and Co-Editor of Dr. Smith’s ECG Blog. He is one of the leading voices behind the Occlusion Myocardial Infarction (OMI) paradigm, the clinical framework that reshaped how heart attacks are identified from the ECG — and which sits at the core of the Queen of Hearts™ model.

Adam Dej

Head of PMcardio for Organizations Engineering

Adam leads engineering for PMcardio for Organizations at Powerful Medical, driving platform architecture, backend systems, and infrastructure behind one of the company’s key growth products. He began programming at 13, entered professional IT at 17, and studied computer security at Comenius University’s Faculty of Mathematics, Physics and Informatics. Known for technical depth across distributed systems, infrastructure, and security, he builds scalable and resilient software with a sharp focus on customer impact. He also champions responsible use of AI and LLMs as force multipliers for modern engineering teams.

Gabriela Rovder Sklencarova

Head of Infrastructure

Gabriela designs the scalable, secure, distributed systems that keep PMcardio running around the clock for clinicians worldwide. She joined from Google, where she was a senior software engineer building core libraries that kept Google’s services resilient against billions of requests, and holds a BA and MA in Computer Science from the University of Cambridge.

Arezou Azar

US and Global Regulatory

Arezou leads Powerful Medical’s global regulatory strategy across the FDA, EU MDR, and international frameworks. She has been part of nearly every major breakthrough in AI cardiology and is an expert in US and global regulatory strategy, SaMD/digital health launches, with experience at Eko Health, Verily, AliveCor, Cardiologs, and Apple. She specializes in regulatory strategy in high-paced global organizations.

Adam Rafajdus

Head of AI

Adam grew into the Head of AI role from MLOps Engineer over six years at Powerful Medical, bringing deep expertise in deep learning and production-grade system deployment. He leads the team behind the Queen of Hearts™ AI ECG models and was awarded Best Poster at ISCE 2025 for the company’s ECG digitization pipeline.

Mike Wall

VP of Sales

Mike brings more than twenty years at UnitedHealth Group to the table, where he served health plans, employer groups, and public-sector entities as a consultative healthcare sales executive. He combines market intelligence, clinical insight, and financial acumen — the three ingredients needed to bring AI-powered diagnostics into US health systems at scale.

Amani Farid

Head of Strategic Partnerships

Amani leads partnership strategy with a hands-on approach to integration, unlocking long-term value through collaboration and scale. A University of Chicago Law School-trained attorney and former M&A and capital markets associate at two top international law firms, she brings the rare combination of legal precision and commercial execution refined across nearly a decade at Stryker and as VP of Corporate Development at RapidAI — spanning medtech, digital health, and AI-driven diagnostics.

Michal Martonak

Commercial Lead

A mathematician by training, Michal leads commercial strategy, go-to-market, and strategic partnerships with healthcare providers and clinical institutions worldwide. He previously built Powerful Medical’s data and clinical partnerships function, acquiring the large-scale clinical datasets that underpin the company’s certified AI models.

Dr. Jozef Bartunek, MD, PhD

Co-founder and VP Clinical Strategy

Interventional cardiologist and Co-director of the Cardiovascular Center in Aalst, Belgium — one of the world’s leading heart centers. A Fogarty International NIH Fellow at Harvard Medical School and visiting Professor of Medicine at Catholic University Leuven, he has authored more than 240 peer-reviewed publications in heart failure and structural heart disease, and anchors Powerful Medical’s clinical and research strategy.

Simon Rovder

Co-founder and CTO

Simon began his engineering career at Microsoft and holds a Master’s degree in Informatics from the University of Edinburgh. He built and scaled Powerful Medical’s technology organization from the ground up to a team of 20+ engineers, leading the architecture of a CE-certified Class IIb medical device now deployed in hospitals across Europe.

Viktor Jurasek

Co-founder and CPO

Viktor was modding computer games before his teens and has spent the last decade shipping digital products across advertising, finance, and healthcare. As co-founder and CPO, he has led PMcardio’s product and design since the first prototype, setting the bar for how a clinical-grade tool should feel in a physician’s hands — fast, clear, and trustworthy at the point of care.

Felix Bauer

Co-founder and COO

Felix was part of the Hyperloop team that repeatedly competed and won in Elon Musk’s SpaceX Hyperloop Pod Competition. He holds a degree from the Technical University of Munich and brings a rare combination of engineering rigor, regulatory discipline, and operational excellence to the company, spearheading operations, compliance, regulatory, quality management, and global market access since day one.

Dr. Robert Herman, MD, PhD

Co-founder and Chief Medical Officer

Robert is a physician-scientist who served on the Research, Digital and Innovation Committee of the European Society of Cardiology. He bridges medicine and AI, connecting clinicians, researchers, regulators, and trial leaders to translate algorithms into clinical practice. He founded multiple AI ECG models, leads international clinical trials validating them, is a recipient of the Journal of the American College of Cardiology Spencer King Award, and was named to Forbes 30 Under 30 Europe 2024.

Martin Herman

Co-founder and CEO

Martin started coding at 14 and moved to Silicon Valley at 18, founding several companies including a US-based startup before returning to Europe with his brother Robert to build Powerful Medical. He comes from a family of doctors, which shaped his conviction that AI belongs wherever it can genuinely save lives. Forbes 30 Under 30 (Europe 2024).

Heart Attacks are #1 cause of death world-wide and killing about 12 milions people a year.

Clinical Definition of Problem

Contrary to popular belief, a heart attacks isn’t a blockage inside of the heart. A heart attack is a blockage of the coronary arteries supplying the heart muscle with oxygenated blood.

So let’s assume you get a blood clot here — it blocks the blood flow downstream, meaning the heart muscle doesn’t get oxygenated blood and heart tissue downstream starts to die.

Clinical Solution​

The way to fix it is relatively simple – doctors put in a stent that opens up the artery and renews blood flow. The latest clinical practice guidelines recommend that this “stenting” happens within 90 minutes from symptom onset.

If you don’t, even if you put in the stent in later, the heart tissue downstream has already been permanently damaged, which reduces the heart’s ability to pump blood. This is the leading cause of heart failure and increases 1-year mortality by two-fold.

Time is muscle.

You have just 90 minutes to diagnose the patient, bring them to the hospital and put in the stent, otherwise there is permanent damage. So problem is, that 1 in 2 heart attacks get initially misdiagnosed at the first point of contact.

Discover the future of medical work with us.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.